FBNC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FBNC looks like a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is supported by strong recent earnings growth, a generally positive analyst stance, and no negative news flow. At 59.18 in pre-market, it is still below the main analyst price targets around 64-66, giving room for upside. While the technical picture is not strongly bullish yet, the broader fundamentals and sentiment are favorable enough to justify buying now rather than waiting.
FBNC is in a mildly constructive but not strongly trending setup. The MACD histogram is slightly negative at -0.0775, but it is contracting, which suggests downside momentum is fading. RSI_6 at 60.588 is neutral to mildly positive, and moving averages are converging, indicating a possible base-building phase rather than a breakdown. Key levels: pivot 58.144, support at 56.255 and 55.088, resistance at 60.033 and 61.2. The pre-market price of 59.18 is above the pivot and near first resistance, so the stock is close to a breakout area rather than deeply oversold. For an impatient long-term buyer, this is acceptable entry behavior.
["Q1 2026 revenue rose 15.02% YoY", "Q1 2026 net income rose 28.86% YoY", "Q1 2026 EPS rose 29.89% YoY", "Analysts remain broadly constructive, with Keefe Bruyette raising the target to $66 and keeping Outperform", "No negative news in the past week", "Options positioning is strongly call-skewed"]
["Piper Sandler downgraded the stock to Neutral in February, saying valuation leaves limited room for multiple expansion", "MACD is still slightly negative", "No recent insider buying support", "No recent hedge fund accumulation trend", "No recent congress trading data"]
In Q1 2026, FBNC delivered solid operating growth. Revenue increased to $119.9 million, up 15.02% YoY, while net income climbed 28.86% YoY to $46.7 million. EPS rose 29.89% YoY to $1.13. This shows strong bottom-line leverage and healthy earnings momentum in the latest quarter season, which is supportive for a long-term banking investment.
Analyst sentiment is mixed but still slightly positive overall. Keefe Bruyette recently raised its price target to $66 from $65 and maintained an Outperform rating, which is constructive. Piper Sandler downgraded the stock to Neutral from Overweight and lifted its target to $64 from $58, citing that the shares already trade around 13.5x 2026 earnings and may have limited room for further multiple expansion. Wall Street’s pro view is that earnings are still improving and targets remain above the current price; the con view is that valuation is no longer cheap. Overall, analysts are positive but not aggressively bullish.
